In This Section

SU2C Canada-Canadian Cancer Society Breast Cancer Dream Team: Translational Development of Novel Drugs Targeting Tumor Vulnerabilities

​Samuel Aparicio, BM, BCh, PhD, FRCPath

​Samuel Aparicio, BM, BCh, PhD, FRCPath

Nan and Lorraine Robertson Chair in Breast Cancer Research
University of British Columbia
Head, Department of Breast and Molecular Oncology
BC Cancer Agency

Tak W. Mak, PhD

Tak W. Mak, PhD

Professor of Medical Biophysics and Immunology
University of Toronto
Director, Campbell Family Institute for Breast Cancer Research
Princess Margaret Cancer Centre


For aggressive forms of breast cancer, treatment options are limited. The Dream Team seeks to expand the range of options by accelerating the development of three new drugs. The first, called CFI-400945, inhibits an enzyme that drives division and proliferation of cells in cancer. The second, CFI-402257, inhibits a molecule that also seems to drive the cancer process. The third, CX5461, works by binding to the replicating DNA and stopping the cell’s copying machinery in its tracks. The Team is also using state-of-the-art approaches to help determine how the three drugs can be used most effectively against breast cancer.